Pharmaceutical Pricing and Healthcare Access

Healthcare coverage and costs remain prime concerns for FDA as the number of uninsured Americans continues to grow.

Related Content:

Regulatory Oversight and CompliancePharmaceutical Technology-03-02-2004

Geopolitical Shifts Change Nature of Pharma Partnerships

FDA Grants Fast Track Designation to Q32 Bio Treatment for Alopecia Areata

CHMP Recommends argenx Treatment for Chronic Inflammatory Demyelinating Polyneuropathy